Bris­tol-My­ers Squibb adds to its ros­ter of check­point com­bo stud­ies, part­ner­ing with Ar­ray and Ad­vax­is

The pa­rade of new im­muno-on­col­o­gy part­ner­ships con­tin­ued Tues­day morn­ing with two new al­liances on the check­point front from Bris­tol-My­ers Squibb $BMY.

Deal #1: Bris­tol-My­ers is step­ping in to work with Ar­ray Bio­Phar­ma on a new dou­ble- and triple-play com­bo for col­orec­tal can­cer. Ar­ray $AR­RY saw its shares surge 8% on the news it will be com­bin­ing its ex­per­i­men­tal MEK in­hibitor binime­tinib with Op­di­vo as well as Op­di­vo plus Yer­voy in a Phase I/II ex­plorato­ry study look­ing at cas­es of col­orec­tal can­cer with sta­ble mi­crosatel­lite tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER